Pigmentation disorder

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Congress, Journal of the European Academy of Dermatology and Venereology, Autoimmunity, Vitiligo, BID, Abstract, Ciclosporin, Inflammation, Depigmentation, Prevalence, Azathioprine, Pigmentation disorder, Melanocyte, American Academy, Week, University, JAK, AAD, Netherlands, Skin, LTE, Patient, Pharmaceutical industry, Dermatology, Venereology, Incyte

These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.

Key Points: 
  • These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Opzelura is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
  • The overall prevalence of the condition is estimated to be approximately 2-3 million2, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo3.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

NEWBEAUTY TOP DOCTOR VALERIE CALLENDER, MD NAMED PRESIDENT OF THE AMERICAN DERMATOLOGICAL ASSOCIATION

Retrieved on: 
Monday, February 6, 2023
Medical director, Woman, American Board of Dermatology, The Washington Campus Board of Directors, American Academy of Dermatology, Pigment, Patient, Pigmentation disorder, Skin, Research, Executive Committee, Hair loss, College, American Board of Commissioners for Foreign Missions, The International League of Dermatological Societies, American Academy, Education, Cosmetic, The College of Medicine, ADA, Howard University, Society, MD, Veterinary medicine, Dermatology

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- NewBeauty is proud to announce that NewBeauty Top Doctor and internationally recognized board-certified dermatologist Valerie Callender, MD has been named President of The American Dermatological Association (ADA).

Key Points: 
  • NEW YORK, Feb. 6, 2023 /PRNewswire/ -- NewBeauty is proud to announce that NewBeauty Top Doctor and internationally recognized board-certified dermatologist Valerie Callender, MD has been named President of The American Dermatological Association (ADA).
  • As an independent, non-profit, self-funded organization, the American Dermatological Association provides objective analyses and recommendations regarding the complex challenges faced by dermatology.
  • She has been an esteemed NewBeauty Top Doctor partner since 2018.
  • To learn more about Dr. Callender and Callender Dermatology and Cosmetic Center and book a consultation, visit callenderskin.com or NewBeauty .

FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

Retrieved on: 
Wednesday, August 17, 2022
FDA, Liver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, Nausea, Cough, Food, Multimedia, Public health, Risk, Oxygen, Office of Inspector General, U.S. Department of Health and Human Services, Hair, Dizziness, Cancer, Animal, Cosmetics, Achievement, Blood, Diarrhea, Rash, Human services, Abdominal pain, Fever, Patient, Beta thalassemia, Hair loss, Fatigue, Cell, Bleeding, Center for Biologics Evaluation and Research, Center, Iron, Mucositis, Itch, Pigmentation disorder, Vaccine, Safety, Febrile neutropenia, Smokeless tobacco, Priority review, Research, Headache, Appetite, Weakness, Lymphatic system, Nosebleed, Heart, Thalassemia, Lists of diseases, China Biologic Products, Dietary supplement, Thrombocytopenia, Adult, Disease, Constipation, Pharmaceutical industry, Betibeglogene autotemcel

SILVER SPRING, Md., Aug. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Key Points: 
  • SILVER SPRING, Md., Aug. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
  • The reduced levels of red blood cells can lead to a number of health issues including dizziness, weakness, fatigue, bone abnormalities and more serious complications.
  • Transfusion-dependent beta-thalassemia, the most severe form of the condition, generally requires life-long red blood cell transfusions as the standard course of treatment.
  • The safety and effectiveness of Zynteglo were established in two multicenter clinical studies that included adult and pediatric patients with beta-thalassemia requiring regular transfusions.

AVAVA Receives FDA 510(k) Clearance to Treat Benign Pigment Lesions, Including Hyperpigmentation

Retrieved on: 
Wednesday, August 17, 2022
FDA, Woman, Map, CEO, GLOBE, Technology, Pigmentation disorder, Pain, Patient, Acne, Skin, Â, Color, X-linked reticulate pigmentary disorder, Hyperpigmentation, Solution, Focal point, Medical device

WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVAVA Inc. (AVAVA or the Company), a disruptive medical aesthetics technology platform company providing breakthrough treatments for all skin tones, today announced that its AVAVA pigment disorder product has received FDA 510(k) clearance to treat benign pigmented lesions of the skin, including hyperpigmentation.

Key Points: 
  • WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVAVA Inc. (AVAVA or the Company), a disruptive medical aesthetics technology platform company providing breakthrough treatments for all skin tones, today announced that its AVAVA pigment disorder product has received FDA 510(k) clearance to treat benign pigmented lesions of the skin, including hyperpigmentation.
  • This clearance marks AVAVAs second received from the FDA for its new class of focused intradermal laser products powered by Focal Point Technology to deliver energy at any depth with pinpoint accuracy for ideal patient outcomes.
  • Dr. Irina Erenburg, CEO of AVAVA, said, We are thrilled to announce our FDA clearance, a key milestone achievement for AVAVA, as we move to address the unmet needs of over 4 million women with pigmentary disorders, a $1 billion annual procedure market.
  • AVAVA is a disruptive medical aesthetics technology platform company providing breakthrough treatments for all skin tones.

Global Functional Cosmetics Market Report 2022-2026: Focus on Conditioning Agents, UV Filters, Anti-Aging Agents, Skin Lightening Agents - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 1, 2022
Cosmetics, Retail, Diagnosis, Blemish, Beauty, Dry, SPF, Skin cancer, Water loss, Population, Filter (signal processing), Government, Cosmetics, USD, Growth, Temperature, Sunscreen, CAGR, Acne, Pigmentation disorder, Climate, Hair, Human, Hair care, Skin, MEA

The "Global Functional Cosmetics Market by Functionality (Conditioning Agents, UV Filters, Anti-Aging Agents, Skin Lightening Agents), Application (Skin Care, and Hair Care), and Region (North America, APAC, Europe, MEA, South America) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Functional Cosmetics Market by Functionality (Conditioning Agents, UV Filters, Anti-Aging Agents, Skin Lightening Agents), Application (Skin Care, and Hair Care), and Region (North America, APAC, Europe, MEA, South America) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the functional cosmetics market is dependent on high spending power on cosmetics and the desire to look beautiful.
  • North America is estimated to be the third-largest functional cosmetics market in 2020, in terms of value
    North America was the third-largest functional cosmetics market in 2020.
  • The improving international economic scenario is contributing to the rising demand for functional cosmetics in various end-use industries in the region.

Global Pigmentation Disorders Treatment Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, December 18, 2020
Health, Other Health, Vitiligo, Pigmentation disorder

Currently, topical treatment is dominating the global market due to the improved clinical outcomes in patients suffering from pigmentation disorders.

Key Points: 
  • Currently, topical treatment is dominating the global market due to the improved clinical outcomes in patients suffering from pigmentation disorders.
  • This factor will boost the market if Ruxolitinib drug gets approved for the treatment of Vitiligo in the near future.
  • North America dominates the global pigmentation disorders treatment market owing to the rising pigmentation disorders.
  • Asia Pacific region is experiencing a swift pace in the global pigmentation disorders treatment market due to the increasing beauty consciousness among Asians, rapid entry of new players into the market and expansion by the major players into the emerging economies.

Global pigmentation disorders treatment market is expected to grow with a CAGR of 5.9% over the forecast period from 2018-2024

Retrieved on: 
Tuesday, March 31, 2020
Forecasting, Statistical forecasting, Supply chain management, Pigmentation disorder

NEW YORK, March 31, 2020 /PRNewswire/ -- The report on the global pigmentation disorders treatment market provides qualitative and quantitative analysis for the period from 2016 to 2024.

Key Points: 
  • NEW YORK, March 31, 2020 /PRNewswire/ -- The report on the global pigmentation disorders treatment market provides qualitative and quantitative analysis for the period from 2016 to 2024.
  • The report predicts the global pigmentation disorders treatment market to grow with a CAGR of 5.9% over the forecast period from 2018-2024.
  • The study on pigmentation disorders treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2016 to 2024.
  • The report on pigmentation disorders treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pigmentation disorders treatment market over the period of 2016 to 2024.

Global Pigmentation Disorders Treatment Markets, 2016-2018 & 2019-2024 by Treatment & Therapies, Disease Indication, End-User, & Region

Retrieved on: 
Thursday, May 2, 2019
Forecasting, Statistical forecasting, Supply chain management, Pigmentation disorder

The report predicts the global pigmentation disorders treatment market to grow with a CAGR of 5.9% over the forecast period from 2018-2024.

Key Points: 
  • The report predicts the global pigmentation disorders treatment market to grow with a CAGR of 5.9% over the forecast period from 2018-2024.
  • The report on the global pigmentation disorders treatment market provides qualitative and quantitative analysis for the period from 2016 to 2024.
  • The report on pigmentation disorders treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pigmentation disorders treatment market over the period of 2016 to 2024.
  • Comprehensive analysis of the global as well as regional markets of the pigmentation disorders treatment market.

Pigmentation Disorders Treatment Market is Expanding at 6.8% CAGR by 2026, With Rise in Overall Geriatric Population, Says TMR

Retrieved on: 
Monday, September 24, 2018
Anatomy, Endocrine system, Transparency Market Research, Pigmentation disorder, Thyroid, Human body, Skin whitening

The pigmentation disorders treatment market is led by Asia Pacific because of rising population, growing awareness about pigmentation disorders product and treatments, and developing economies.

Key Points: 
  • The pigmentation disorders treatment market is led by Asia Pacific because of rising population, growing awareness about pigmentation disorders product and treatments, and developing economies.
  • Improved lifestyle combined with rising demand for skin lightening is foreseen to be the essential factor driving the pigmentation disorders treatment market.
  • Rise in geriatric population, rise in number of smokers all over the world, rising occurrence rates for skin disorders, global warming and surging per capita income are some different variables energizing the pigmentation disorders treatment market.
  • Popular Research Reports by TMR:
    Thyroid Gland Disorders Treatment Market: https://www.transparencymarketresearch.com/thyroid-gland-disorder-market...
    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services.

Pigmentation Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Monday, August 13, 2018
Medicine, Systems biology, Dermatology, Hypopigmentation, Vitiligo, Melasma, Photorejuvenation, Pigmentation disorder

NEW YORK, August 13, 2018 /PRNewswire/ -- Global Pigmentation Disorders Treatment Market: Overview

Key Points: 
  • NEW YORK, August 13, 2018 /PRNewswire/ -- Global Pigmentation Disorders Treatment Market: Overview
    This report analyzes the global pigmentation disorders treatment market in terms of its current and future scenario.Rise in investment in R&D of novel advanced technologies, decrease in social taboos regarding pigmentation, increase in prevalence of pigmentation-related disorders, and rise in awareness about skin rejuvenation and treatment options are likely to drive the expansion of the global market during the forecast period.
  • It also provides market attractiveness analysis in terms of geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global pigmentation disorders treatment market.
  • Global Pigmentation Disorders Treatment Market: Key Segments
    Based on treatment, the global pigmentation disorders treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others.In terms of disease indication, the market has been classified into hyperpigmentation (melasma, post-inflammatory hyperpigmentation, solar lentigines, and others) and hypopigmentation (vitiligo, albinism, and others).
  • The global pigmentation disorders treatment market has been segmented as follows: